Atomwise, a pioneering preclinical pharmaceutical company, has announced a significant funding milestone, successfully securing $175 million from top venture capital firms to fuel its groundbreaking approach to drug discovery using artificial intelligence. As a leader in the field, Atomic’s proprietary AtomNet® technology has revolutionized the search for effective treatments by employing deep learning to identify viable small-molecule drug candidates. With this recent funding, the company aims to fortify its internal pipeline of innovative drug candidates and tackle over 600 unique disease targets in collaboration with its 250 partners worldwide, including esteemed names in pharmaceuticals, agrochemicals, and biotechnology.
This announcement comes at a pivotal moment, as Atomwise has not only expanded its expertise through strategic appointments to its Board of Directors and the formation of a Scientific Advisory Board (SAB), but also reaffirms its commitment to advancing medicine in an era when the demand for new treatments has never been more critical. By harnessing the power of AI and cutting-edge scientific breakthroughs, Atomwise is positioned to expedite drug discovery and development, addressing some of healthcare's most pressing challenges. With this considerable infusion of capital, Atomwise is set to push the boundaries of innovation in pharmaceutical development, aiming to create transformative therapies that have the potential to improve and save millions of lives globally. As they embark on this ambitious journey, Atomwise invites passionate individuals to join their mission at www.atomwise.com/careers.
